Help them let go of their transfusions with ZYNTEGLO

Actor portrayal
Beta-thalassemia transfusion independence

A one-time gene therapy that gives people with beta-thalassemia the potential to become free from regular red blood cell transfusions.1

Help them let go of their transfusions with ZYNTEGLO

A one-time gene therapy that gives people with beta-thalassemia the potential to become free from regular red blood cell transfusions.1

See Clinical Trial Results

In two open-label, single-arm studies, 89% (n=32/36; 95% CI: 74, 97) of patients across ages and genotypes achieved transfusion independence (TI) with a median weighted average total Hb during TI of 11.5 g/dL (min, max: 9.3, 13.7).1*

CI = confidence interval.
*Transfusion independence: a weighted average Hb ≥9 g/dL without any packed red blood cell transfusions for a continuous period of ≥12 months at any time during the study after ZYNTEGLO infusion.1

The phase 3 studies evaluated the efficacy of ZYNTEGLO in 41 patients. Of those 41 patients, 36 were evaluable for transfusion independence.

Actor portrayals
Beta-thalassemia transfusion independence
Talk to your patients about ZYNTEGLO; get a discussion guide to help
Answer 5 questions to create a downloadable discussion guide to support your conversations
Find support for you and your patients
Learn about my bluebird support, download the ZYNTEGLO Patient and Caregiver Brochure, and find additional resources available for you
Back
to Top
Submitting form...

Stay Connected

Stay Connected

Sign up to receive emails for additional ZYNTEGLO information and resources